If you are wondering whether Teva Pharmaceutical Industries' current share price lines up with its underlying worth, you are in the right place to unpack what the market might be pricing in. Teva's ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...

Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) published two positive announcements yesterday. The first concerns ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

The company‘s 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism.

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Teva Pharmaceuticals can’t delay the first trial in thousands of lawsuits over claims its Paragard intrauterine contraceptive ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the ...

Most of the original Israeli investors - mainly OrbiMed and Pontifax Venture Capital - exited around the IPO, and as far as ...

Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO ® (deutetrabenazine), AJOVY ® (fremanezumab), ...